FIELD: medicine.SUBSTANCE: patient is pre-examined to determine a risk of the unfavourable outcome and a rate of disease progression. The risk of the unfavourable outcome is evaluated by specific formula. A period of the onset of the symptoms to diagnosis, a functional class at the time of diagnosis, a cardiac output at the time of diagnosis, acute pharmacological sample test results are taken into consideration. The disease progression rate is also established by the estimated functional class (FC) by 6 months of assessment by specific formula. That involves taking into account the functional class at the time of diagnosis, a systolic pressure in the pulmonary artery according to catheterisation of the pulmonary heart, a 6 minute walking distance, Borg scale index, a right atrium area according to echocardiography. If that results in stating the low risk of the unfavourable outcome alongside with the stable clinical course in the patient, a standard medical treatment including administering warfarin or acetylsalicylic acid, diuretics, cardiac glycosides, calcium antagonists is conducted. If the patient shows the low risk of the unfavourable outcome accompanied by the disease progression, the standard medical treatment is added with a vasodilator that is inhalable nitrogen oxide (iNO) or prostaglandin E1 (PGE1). If the moderate risk of the unfavourable outcome and the stable clinical course are stated in the patient, the standard medical treatment is added with therapeutic courses by administering vasodilators iNO and PGE1. If the patient has the moderate risk of the unfavourable outcome with the disease progression, or the high risk of the unfavourable outcome and the stable clinical course of the disease, or the high risk of the unfavourable outcome and the disease progression, the standard medical treatment is added with bosentan.EFFECT: higher clinical effectiveness and reducing a number of lethal outcomes in the patients with idiopathic pulmonary arterial hyper
